00:30 , Jan 25, 2019 |  BC Week In Review  |  Company News

Camp4, Alnylam partner to identify liver disease targets with machine learning

Camp4 Therapeutics Corp. (Cambridge, Mass.) will deploy its Gene Circuitry Platform under a deal with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) to identify new targets for an undisclosed rare liver disease. CAMP4's platform uses machine learning to...
21:02 , Jan 23, 2019 |  BC Extra  |  Company News

Camp4, Alnylam partner to identify liver disease targets with machine learning

Camp4 Therapeutics Corp. (Cambridge, Mass.) will deploy its Gene Circuitry Platform under a deal with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) to identify new targets for an undisclosed rare liver disease. CAMP4's platform uses machine learning to...
14:20 , Jul 12, 2018 |  BC Innovations  |  Emerging Company Profile

Gene control goals

By mapping all of the signaling pathways and transcription factors that control the expression of every gene in a cell type of interest, Camp4 Therapeutics Corp. is betting its machine learning-based platform will be able...
19:31 , Jun 1, 2018 |  BC Week In Review  |  Financial News

CAMP4 Therapeutics launches with $30M series A

CAMP4 Therapeutics Corp. (Cambridge, Mass.) launched on May 31 with an untranched $30 million series A round led by new investor Andreessen Horowitz. Existing investors The Kraft Group and Polaris Partners also participated. A CAMP4...
12:31 , May 31, 2018 |  BC Extra  |  Financial News

CAMP4 Therapeutics launches with $30M series A

CAMP4 Therapeutics Corp. (Cambridge, Mass.) launched with an untranched $30 million series A round led by new investor Andreessen Horowitz. Existing investors The Kraft Group and Polaris Partners also participated. A CAMP4 spokesperson told BioCentury...